Barrington Research initiates Viemed Healthcare with Outperform rating
Barrington Research initiated coverage of Viemed Healthcare with an outperform rating and a $14.00 price target. Freedom Capital cut the stock from strong buy to hold. Analysts’ consensus is hold with an average target of $14.00. The director sold shares at about $11.72, and investors including the State of Alaska and Globeflex Capital bought new stakes.